SynthesisFrontiers in public health2022
Cost-Effectiveness of Population Screening Programs for Cardiovascular Diseases and Diabetes in Low- and Middle-Income Countries: A Systematic Review.
Synthesis in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Community-integrated noncommunicable disease service models: lessons from China.Journal of global health · 2025Pooled it
- Ten Recommendations for Modelling Cost Effectiveness of Screening: Perspectives of an International Stakeholder Group.PharmacoEconomics · 2026Review
- Article
- People with severe mental illness have low rates of screening for non-communicable diseases: Findings of a multi-country cross-sectional study in South Asia.Global mental health (Cambridge, England) · 2026Article
- Cancer screening as a double-edged sword: short-term cost surge and cross-sectional expenditure patterns among urban retirees in Jiangsu, China.Frontiers in public health · 2026Article
- Lean type 2 diabetes: the overlooked epidemic reshaping global health.Diabetology & metabolic syndrome · 2025Review
- Global, regional and national burden of blindness and vision loss attributable to diabetic retinopathy, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021.Diabetes, obesity & metabolism · 2025Article
- Association of KCNJ11 rs5219 polymorphism with risk of type 2 diabetes and its cardiovascular and renal complications in Noakhali, Bangladesh.Scientific reports · 2025Article
- Application of decision analytic modelling to cardiovascular disease prevention in Sub-Saharan Africa: a systematic review.Communications medicine · 2025Article
- Barriers to and facilitators of linkage to care following hypertension and diabetes screening among health workers in Zimbabwe: A mixed method study.PLOS global public health · 2025Article
- Associations of work characteristics with obesity, behavioral risk factors and NCDs in Bangkok, Thailand.PLOS global public health · 2024Article
- Cardiovascular risk assessment using non-laboratory based WHO CVD risk prediction chart with respect to hypertension status among older Indian adults: insights from nationally representative survey.Frontiers in public health · 2024Article
- Optimizing cardiovascular disease risk screening in a low-resource setting: cost-effectiveness of program modifications in Sri Lanka modelled with nationally representative survey data.BMC public health · 2023Article
- One-Hour Post-Load Plasma Glucose and Altered Glucometabolic Profile in Youths with Overweight or Obesity.International journal of environmental research and public health · 2023Article
- Cost-effectiveness of non-communicable disease prevention in Southeast Asia: a scoping review.Frontiers in public health · 2023Article
- Cost of "Ideal Minimum Integrated Care" for Type 2 Diabetes and Hypertension Patients in Cambodia Context: Provider Perspective.International journal of integrated careArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Almost all low- and middle-income countries (LMICs) have instated a program to control and manage non-communicable diseases (NCDs). Population screening is an integral component of this strategy and requires a substantial chunk of investment. Therefore, testing the screening program for economic along with clinical effectiveness is essential. There is significant proof of the benefits of incorporating economic evidence in health decision-making globally, although evidence from LMICs in NCD prevention is scanty. This systematic review aims to consolidate and synthesize economic evidence of screening programs for cardiovascular diseases (CVD) and diabetes from LMICs. The study protocol is registered on PROSPERO (CRD42021275806). The review includes articles from English and Chinese languages. An initial search retrieved a total of 2,644 potentially relevant publications. Finally, 15 articles (13 English and 2 Chinese reports) were included and scrutinized in detail. We found 6 economic evaluations of interventions targeting cardiovascular diseases, 5 evaluations of diabetes interventions, and 4 were combined interventions, i.e., screening of diabetes and cardiovascular diseases. The study showcases numerous innovative screening programs that have been piloted, such as using mobile technology for screening, integrating non-communicable disease screening with existing communicable disease screening programs, and using community health workers for screening. Our review reveals that context is of utmost importance while considering any intervention, i.e., depending on the available resources, cost-effectiveness may vary-screening programs can be made universal or targeted just for the high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.